1541 Stock Overview
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$14.06 |
| 52 Week High | HK$32.15 |
| 52 Week Low | HK$13.58 |
| Beta | 0 |
| 1 Month Change | -4.09% |
| 3 Month Change | -36.95% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1541 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.9% | 4.8% | 2.2% |
| 1Y | n/a | -34.7% | -7.9% |
Return vs Industry: Insufficient data to determine how 1541 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1541 performed against the Hong Kong Market.
Price Volatility
| 1541 volatility | |
|---|---|
| 1541 Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1541's share price has been volatile over the past 3 months.
Volatility Over Time: 1541's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 145 | Tian Wenzhi | www.immuneonco.com |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamentals Summary
| 1541 fundamental statistics | |
|---|---|
| Market cap | HK$5.26b |
| Earnings (TTM) | -HK$409.72m |
| Revenue (TTM) | HK$416.79k |
Over9,999x
P/S Ratio-12.8x
P/E RatioIs 1541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1541 income statement (TTM) | |
|---|---|
| Revenue | CN¥386.00k |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥386.00k |
| Other Expenses | CN¥379.85m |
| Earnings | -CN¥379.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -98,305.44% |
| Debt/Equity Ratio | 8.0% |
How did 1541 perform over the long term?
See historical performance and comparison